L2M - NSERC Development of a tool for diagnosis of diabetic complications

这里的研究人员提议开发一种软件应用程序，可以利用人工智能和机器学习来使用输入的生物标志物水平来诊断疾病。该软件应用程序将首先为糖尿病导致失明的疾病定制，也被称为糖尿病视网膜病变(DR)。查克拉巴蒂博士和他的团队在世界发现公司的协助下，已经申请了一项目前处于PCT阶段的专利(PCT/CA2021/050924)。目前的技术使用一组基因的表达水平来诊断患者是否已经发展为DR，以及他们处于什么阶段。患者存在差异，该团队目前正在测试另外500名患者，以验证生物标记物技术(已提交专利申请)。这项研究的数据将输入到目前计划开发的软件应用程序中。这将使家庭医生和眼科医生能够更准确地将实验室测试的数据输入到这个系统中，以准确地诊断疾病的进展。此外，该应用程序还将开发用于其他依赖于生物标志物水平的疾病诊断。目前的软件应用算法将针对特定疾病的使用而量身定制。目标将是与生物标记物检测小组和中心合作，将现有软件整合到他们的工作流程中。目前的技术作为一种软件应用，将是在使用生物标记物识别和验证疾病这一快速增长的领域中使用的第一项此类技术。

The researchers here propose developing a software application that can leverage artificial intelligence and machine learning to diagnose a disease using inputted biomarker levels. The software application would first be customized for disease causing blindness in diabetes, also known as diabetic retinopathy (DR). Dr. Chakrabarti and his team, with the assistance of WORLDiscoveries, have filed for a patent currently at the PCT stage (PCT/CA2021/050924). The current technology uses expression levels of a set of genes to diagnose if the patient has developed DR and what stage they are at. Patient differences exist, and the team is currently testing 500 additional patients to validate the biomarker technology (patent application filed). The data from this study will be fed into the current software application that has been planned to be developed. This will allow with much accuracy, family physicians and ophthalmologists to enter the data from the laboratory test into this system to accurately diagnose the progression of the disease.Furthermore, the application will also be developed for other disease diagnoses that are biomarker level dependent. The current software application algorithm will be tailored to disease-specific use. The goal will be to partner with biomarker testing panels and centres to integrate the existing software into their workflow. The current technology as a software application would the first of its kind to be used in the rapidly growing field of using biomarkers to identify and validate diseases.